On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas. The news coincided with the...
Guo X, Mahlakõiv T, Ye Q, et al. CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 2021;9:e001975. doi: 10.1136/jitc-2020-001975 Abstract Background Tumors often develop resistance to...
As a company leading the innovation in off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases, Celularity has the humble honor of presenting its brand new digital branding package...
LifebankUSA, powered by Celularity Inc, and the world’s most comprehensive company for cord, placenta and tissue banking, today unveils a brand new website and announces a relocation to new headquarters...
Therapeutics startup Celularity announced Thursday morning that it has received FDA clearance to begin a clinical trial of a proposed stem-cell treatment for COVID-19. The approval of the New Jersey-based...
Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential...
JTNDaWZyYW1lJTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZjaGVkZGFyLmNvbSUyRm1lZGlhJTJGY2VsdWxhcml0eS1nZXRzLWZkYS1hcHByb3ZhbC1tb3Zlcy10b3dhcmQtbmV3LWNvcm9uYXZpcnVzLXRyZWF0bWVudCUyRnBsYXllciUzRmF1dG9wbGF5JTNEZmFsc2UlMjIlMjB3aWR0aCUzRCUyMjkwMCUyMiUyMGhlaWdodCUzRCUyMjUwMCUyMiUyMGZyYW1lYm9yZGVyJTNEJTIyMCUyMiUyMGFsbG93ZnVsbHNjcmVlbiUzRSUzQyUyRmlmcmFtZSUzRQ==Dr. Robert Hariri, CEO and founder of Celularity, discusses how the company is exploring a new treatment for COVID-19 as the pandemic intensifies.
The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer. CYNK-001 (Celularity) is an investigational, cryopreserved, allogeneic...
Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of...
Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials
CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
Celularity Announces Brand New Website
Lifebank Debuts New Branding & Announces Move to New Facility
FDA Green-Lights Clinical Trial For COVID-19 Coronavirus Treatment That ‘Flattens The Curve’ In Patients
Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19
Celularity Gets FDA Approval, Moves Toward New Coronavirus Treatment
FDA clears IND application for natural killer cell-based COVID-19 therapy
Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID